Ori Biotech taps MD Anderson, National Resilience joint venture to put its automated cell and gene therapy manufacturing tech to the test

Sep 15, 2022

Article Link: https://www.fiercepharma.com/manufacturing/ori-biotech-taps-md-anderson-national-resilience-jv-put-its-automated-cell-and-gene

Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez

May 7, 2026

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...

May 5, 2026

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...

Apr 17, 2026

CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change...

Back